These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20425407)

  • 1. Vaccination strategies in follicular lymphoma.
    Kannan S; Neelapu SS
    Curr Hematol Malig Rep; 2009 Oct; 4(4):189-95. PubMed ID: 20425407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational development of vaccination strategies in follicular NHL.
    Sakamaki I; Qin H; Kwak LW
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiotype vaccine strategies for treatment of follicular lymphoma.
    Mahaseth H; Brody JD; Sinha R; Shenoy PJ; Flowers CR
    Future Oncol; 2011 Jan; 7(1):111-22. PubMed ID: 21174542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure.
    Longo DL
    J Natl Cancer Inst; 2006 Sep; 98(18):1263-5. PubMed ID: 16985240
    [No Abstract]   [Full Text] [Related]  

  • 6. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
    Neelapu SS; Baskar S; Gause BL; Kobrin CB; Watson TM; Frye AR; Pennington R; Harvey L; Jaffe ES; Robb RJ; Popescu MC; Kwak LW
    Clin Cancer Res; 2004 Dec; 10(24):8309-17. PubMed ID: 15623607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of idiotype vaccines in the treatment of human B-cell malignancies.
    Bendandi M
    Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
    Yáñez R; Barrios Y; Ruiz E; Cabrera R; Díaz-Espada F
    J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
    Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
    Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines for lymphomas: idiotype vaccines and beyond.
    Houot R; Levy R
    Blood Rev; 2009 May; 23(3):137-42. PubMed ID: 18951668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.
    Park HJ; Neelapu SS
    Br J Haematol; 2008 Jun; 142(2):179-91. PubMed ID: 18422783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Flowers CR
    Expert Rev Vaccines; 2007 Jun; 6(3):307-17. PubMed ID: 17542746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
    Inogès S; Rodrìguez-Calvillo M; Zabalegui N; Lòpez-Dìaz de Cerio A; Villanueva H; Soria E; Suárez L; Rodríguez-Caballero A; Pastor F; García-Muñóz R; Panizo C; Pèrez-Calvo J; Melero I; Rocha E; Orfao A; Bendandi M; ;
    J Natl Cancer Inst; 2006 Sep; 98(18):1292-301. PubMed ID: 16985248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
    Schuster SJ; Neelapu SS; Gause BL; Janik JE; Muggia FM; Gockerman JP; Winter JN; Flowers CR; Nikcevich DA; Sotomayor EM; McGaughey DS; Jaffe ES; Chong EA; Reynolds CW; Berry DA; Santos CF; Popa MA; McCord AM; Kwak LW
    J Clin Oncol; 2011 Jul; 29(20):2787-94. PubMed ID: 21632504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of predicted HLA binding of immunoglobulin idiotype sequences indicates T cell-mediated immunosurveillance in follicular lymphoma.
    Strothmeyer AM; Papaioannou D; Dühren-von Minden M; Navarrete M; Zirlik K; Heining-Mikesch K; Veelken H
    Blood; 2010 Sep; 116(10):1734-6. PubMed ID: 20522710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
    Bendandi M
    Nat Rev Cancer; 2009 Sep; 9(9):675-81. PubMed ID: 19701243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
    Hurvitz SA; Timmerman JM
    Expert Opin Biol Ther; 2005 Jun; 5(6):841-52. PubMed ID: 15952914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.
    McCormick AA; Reddy S; Reinl SJ; Cameron TI; Czerwinkski DK; Vojdani F; Hanley KM; Garger SJ; White EL; Novak J; Barrett J; Holtz RB; Tusé D; Levy R
    Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10131-6. PubMed ID: 18645180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.
    Lee ST; Jiang YF; Park KU; Woo AF; Neelapu SS
    Expert Opin Biol Ther; 2007 Jan; 7(1):113-22. PubMed ID: 17150023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.